BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wang B, Santoreneos R, Giles L, Haji Ali Afzali H, Marshall H. Case fatality rates of invasive meningococcal disease by serogroup and age: A systematic review and meta-analysis. Vaccine 2019;37:2768-82. [DOI: 10.1016/j.vaccine.2019.04.020] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 12.0] [Reference Citation Analysis]
Number Citing Articles
1 Earle SG, Lobanovska M, Lavender H, Tang C, Exley RM, Ramos-Sevillano E, Browning DF, Kostiou V, Harrison OB, Bratcher HB, Varani G, Tang CM, Wilson DJ, Maiden MCJ. Genome-wide association studies reveal the role of polymorphisms affecting factor H binding protein expression in host invasion by Neisseria meningitidis. PLoS Pathog 2021;17:e1009992. [PMID: 34662348 DOI: 10.1371/journal.ppat.1009992] [Reference Citation Analysis]
2 Marín JEO, Villatoro E, Luna MJ, Barrientos AM, Mendoza E, Lemos APS, Camargo CH, Sacchi CT, Cunha MPV, Galas M, Gabastou JM. Emergence of MDR invasive Neisseria meningitidis in El Salvador, 2017-19. J Antimicrob Chemother 2021;76:1155-9. [PMID: 33517418 DOI: 10.1093/jac/dkab010] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
3 Navarro-Carrera P, García-Rodríguez J, Cendejas-Bueno E. Detection of Neisseria meningitidis in a patient receiving ravulizumab by the FilmArray® Meningitis/Encephalitis panel- A case report. J Infect 2021;82:e22-3. [PMID: 33762163 DOI: 10.1016/j.jinf.2021.03.014] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Marshall HS. Meningococcal surveillance in Southeast Asia and the Pacific. Microbiol Aust 2021;42:178. [DOI: 10.1071/ma21050] [Reference Citation Analysis]
5 Ghaswalla PK, Bengtson LGS, Marshall GS, Buikema AR, Bancroft T, Schladweiler KM, Koep E, Novy P, Hogea CS. Meningococcal vaccination in patients with newly diagnosed asplenia in the United States. Vaccine 2021;39:272-81. [PMID: 33309081 DOI: 10.1016/j.vaccine.2020.11.068] [Reference Citation Analysis]
6 Platten M, Aladellie L. Neisseria meningitidis serogroup W(P1.5-2) sepsis presenting with myopericarditis in an elderly previously healthy male. IDCases 2021;25:e01238. [PMID: 34377672 DOI: 10.1016/j.idcr.2021.e01238] [Reference Citation Analysis]
7 Kleinschmidt A, Vadivelu K, Serino L, Neidig N, de Wergifosse B. Endogenous complement human serum bactericidal assay (enc-hSBA) for vaccine effectiveness assessments against meningococcal serogroup B. NPJ Vaccines 2021;6:29. [PMID: 33623041 DOI: 10.1038/s41541-021-00286-8] [Reference Citation Analysis]
8 Ohm M, Hahné SJM, van der Ende A, Sanders EAM, Berbers GAM, Ruijs WLM, van Sorge NM, de Melker HE, Knol MJ. Vaccine impact and effectiveness of meningococcal serogroup ACWY conjugate vaccine implementation in the Netherlands: a nationwide surveillance study. Clin Infect Dis 2021:ciab791. [PMID: 34525199 DOI: 10.1093/cid/ciab791] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Watle SV, Næss LM, Tunheim G, Caugant DA, Wisløff T. Cost-effectiveness of meningococcal vaccination of Norwegian teenagers with a quadrivalent ACWY conjugate vaccine. Hum Vaccin Immunother 2021;17:2777-87. [PMID: 33631080 DOI: 10.1080/21645515.2021.1880209] [Reference Citation Analysis]
10 Marshall HS, Andraweera PH, Wang B, McMillan M, Koehler AP, Lally N, Almond S, Denehy E, A'Houre M, Giles LC, Flood L. Evaluating the effectiveness of the 4CMenB vaccine against invasive meningococcal disease and gonorrhoea in an infant, child and adolescent program: protocol. Hum Vaccin Immunother 2021;17:1450-4. [PMID: 33428528 DOI: 10.1080/21645515.2020.1827614] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
11 Borrow R, Taha MK, Giuliani MM, Pizza M, Banzhoff A, Bekkat-Berkani R. Methods to evaluate serogroup B meningococcal vaccines: From predictions to real-world evidence. J Infect 2020;81:862-72. [PMID: 32745637 DOI: 10.1016/j.jinf.2020.07.034] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
12 Díez-Domingo J, Tinoco JC, Poder A, Dinleyici EC, Nell H, Salamanca de la Cueva I, Ince T, Moreira ED Jr, Ahmed K, Luz K, Kovshirina Y, Medina Pech CE, Akhund T, Romolini V, Costantini M, Mzolo T, Kunnel B, Lechevin I, Aggravi M, Tiberi P, Narendran K, García-Martínez JA, Basile V, Fragapane E, Lattanzi M, Pellegrini M. Immunological non-inferiority of a new fully liquid presentation of the MenACWY-CRM vaccine to the licensed vaccine: results from a randomized, controlled, observer-blind study in adolescents and young adults. Hum Vaccin Immunother 2021;:1-9. [PMID: 34614379 DOI: 10.1080/21645515.2021.1981085] [Reference Citation Analysis]
13 Ghaswalla PK, Marshall GS, Bengtson LGS, Buikema AR, Bancroft T, Koep E, Novy P, Hogea CS. Meningococcal Vaccination Rates Among People With a New Diagnosis of HIV Infection in the US. JAMA Netw Open 2022;5:e228573. [PMID: 35486405 DOI: 10.1001/jamanetworkopen.2022.8573] [Reference Citation Analysis]
14 Marshall HS, Lally N, Flood L, Phillips P. First statewide meningococcal B vaccine program in infants, children and adolescents: evidence for implementation in South Australia. Med J Aust 2020;212:89-93. [PMID: 31909501 DOI: 10.5694/mja2.50481] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
15 Basu N, Ghosh R. Recent chemical syntheses of bacteria related oligosaccharides using modern expeditious approaches. Carbohydr Res 2021;507:108295. [PMID: 34271477 DOI: 10.1016/j.carres.2021.108295] [Reference Citation Analysis]
16 Marshall GS, Fergie J, Presa J, Peyrani P. Rationale for the Development of a Pentavalent Meningococcal Vaccine: A US-Focused Review. Infect Dis Ther 2022. [PMID: 35357651 DOI: 10.1007/s40121-022-00609-9] [Reference Citation Analysis]
17 Wang B, Haji Ali Afzali H, Giles L, Marshall H. Lifetime costs of invasive meningococcal disease: A Markov model approach. Vaccine 2019;37:6885-93. [PMID: 31594708 DOI: 10.1016/j.vaccine.2019.09.060] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
18 Manuel AR, Vieira J, Figueiredo A, Correia P. Invasive meningococcal disease: should the first episode prompt further investigation? J Paediatr Child Health 2021. [PMID: 34672415 DOI: 10.1111/jpc.15768] [Reference Citation Analysis]
19 Guedes S, Bertrand-Gerentes I, Evans K, Coste F, Oster P. Invasive meningococcal disease in older adults in North America and Europe: is this the time for action? A review of the literature. BMC Public Health 2022;22:380. [PMID: 35197024 DOI: 10.1186/s12889-022-12795-9] [Reference Citation Analysis]
20 Gruhn S, Witte J, Greiner W, Damm O, Dietzsch M, Kramer R, Knuf M. Epidemiology and economic burden of meningococcal disease in Germany: A systematic review. Vaccine 2022. [DOI: 10.1016/j.vaccine.2022.02.043] [Reference Citation Analysis]
21 Martinón-Torres F, Taha MK, Knuf M, Abbing-Karahagopian V, Pellegrini M, Bekkat-Berkani R, Abitbol V. Evolving strategies for meningococcal vaccination in Europe: Overview and key determinants for current and future considerations. Pathog Glob Health 2021;:1-14. [PMID: 34569453 DOI: 10.1080/20477724.2021.1972663] [Reference Citation Analysis]
22 Aye AMM, Bai X, Borrow R, Bory S, Carlos J, Caugant DA, Chiou CS, Dai VTT, Dinleyici EC, Ghimire P, Handryastuti S, Heo JY, Jennison A, Kamiya H, Tonnii Sia L, Lucidarme J, Marshall H, Putri ND, Saha S, Shao Z, Sim JHC, Smith V, Taha MK, Van Thanh P, Thisyakorn U, Tshering K, Vázquez J, Veeraraghavan B, Yezli S, Zhu B. Meningococcal disease surveillance in the Asia-Pacific region (2020): The global meningococcal initiative. J Infect 2020;81:698-711. [PMID: 32730999 DOI: 10.1016/j.jinf.2020.07.025] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
23 Pace D, Gauci C, Barbara C. The epidemiology of invasive meningococcal disease and the utility of vaccination in Malta. Eur J Clin Microbiol Infect Dis 2020;39:1885-97. [PMID: 32418063 DOI: 10.1007/s10096-020-03914-8] [Reference Citation Analysis]
24 Kirstein J, Pina M, Pan J, Jordanov E, Dhingra MS. Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in adults 56 years of age and older: a Phase II randomized study. Hum Vaccin Immunother 2020;16:1299-305. [PMID: 32233961 DOI: 10.1080/21645515.2020.1733868] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
25 Caugant DA, Brynildsrud OB. Neisseria meningitidis: using genomics to understand diversity, evolution and pathogenesis. Nat Rev Microbiol 2020;18:84-96. [PMID: 31705134 DOI: 10.1038/s41579-019-0282-6] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 6.7] [Reference Citation Analysis]
26 Shen J, Bouée S, Aris E, Emery C, Beck EC. Long-Term Mortality and State Financial Support in Invasive Meningococcal Disease-Real-World Data Analysis Using the French National Claims Database (SNIIRAM). Infect Dis Ther 2021. [PMID: 34791633 DOI: 10.1007/s40121-021-00546-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Hansen CE, Niccolai LM. Factors Associated With Receipt of Meningococcal B Vaccine Among United States Adolescents, National Immunization Survey-Teen, 2017-2018. J Adolesc Health 2021:S1054-139X(21)00226-3. [PMID: 34148798 DOI: 10.1016/j.jadohealth.2021.04.029] [Reference Citation Analysis]
28 Richardson E, Ryan KA, Lawrence RM, Harle CA, Desai SM, Livingston MD, Rawal A, Staras SAS. Increasing awareness and uptake of the MenB vaccine on a large university campus. Hum Vaccin Immunother 2021;17:3239-46. [PMID: 34076556 DOI: 10.1080/21645515.2021.1923347] [Reference Citation Analysis]
29 Richardson E, Ryan KA, Lawrence RM, Harle CA, Young A, Livingston MD, Rawal A, Staras SAS. Perceptions and Knowledge About the MenB Vaccine Among Parents of High School Students. J Community Health 2021;46:808-16. [PMID: 33389475 DOI: 10.1007/s10900-020-00954-1] [Reference Citation Analysis]
30 de Oliveira Bressane Lima P, van Lier A, de Melker H, Ferreira JA, van Vliet H, Knol MJ. MenACWY vaccination campaign for adolescents in the Netherlands: Uptake and its determinants. Vaccine 2020;38:5516-24. [PMID: 32593605 DOI: 10.1016/j.vaccine.2020.05.087] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
31 Taha MK, Martinon-Torres F, Köllges R, Bonanni P, Safadi MAP, Booy R, Smith V, Garcia S, Bekkat-Berkani R, Abitbol V. Equity in vaccination policies to overcome social deprivation as a risk factor for invasive meningococcal disease. Expert Rev Vaccines 2022. [PMID: 35271781 DOI: 10.1080/14760584.2022.2052048] [Reference Citation Analysis]
32 Ruiz Garcia Y, Abitbol V, Pellegrini M, Bekkat-Berkani R, Soumahoro L. A Decade of Fighting Invasive Meningococcal Disease: A Narrative Review of Clinical and Real-World Experience with the MenACWY-CRM Conjugate Vaccine. Infect Dis Ther 2021. [PMID: 34591258 DOI: 10.1007/s40121-021-00519-2] [Reference Citation Analysis]
33 Dubey H, Oster P, Fazeli MS, Guedes S, Serafini P, Leung L, Amiche A. Risk Factors for Contracting Invasive Meningococcal Disease and Related Mortality: A Systematic Literature Review and Meta-analysis. Int J Infect Dis 2022;119:1-9. [PMID: 35339714 DOI: 10.1016/j.ijid.2022.03.032] [Reference Citation Analysis]
34 Willerton L, Lucidarme J, Walker A, Lekshmi A, Clark SA, Walsh L, Bai X, Lee-Jones L, Borrow R. Antibiotic resistance among invasive Neisseria meningitidis isolates in England, Wales and Northern Ireland (2010/11 to 2018/19). PLoS One 2021;16:e0260677. [PMID: 34843604 DOI: 10.1371/journal.pone.0260677] [Reference Citation Analysis]
35 Mikucki A, Mccluskey NR, Kahler CM. The Host-Pathogen Interactions and Epicellular Lifestyle of Neisseria meningitidis. Front Cell Infect Microbiol 2022;12:862935. [DOI: 10.3389/fcimb.2022.862935] [Reference Citation Analysis]
36 Vandermeulen C, Leroux-Roels I, Vandeleur J, Staniscia T, Girard G, Ferguson M, Icardi G, Schwarz TF, Neville AM, Nolan T, Cinquetti S, Akhund T, Van Huyneghem S, Aggravi M, Kunnel B, de Wergifosse B, Domenico GFD, Costantini M, Vir Singh P, Fragapane E, Lattanzi M, Pellegrini M. A new fully liquid presentation of MenACWY-CRM conjugate vaccine: Results from a multicentre, randomised, controlled, observer-blind study. Vaccine 2021;39:6628-36. [PMID: 34635373 DOI: 10.1016/j.vaccine.2021.09.068] [Reference Citation Analysis]
37 Pizza M, Bekkat-Berkani R, Rappuoli R. Vaccines against Meningococcal Diseases. Microorganisms 2020;8:E1521. [PMID: 33022961 DOI: 10.3390/microorganisms8101521] [Cited by in Crossref: 22] [Cited by in F6Publishing: 13] [Article Influence: 11.0] [Reference Citation Analysis]
38 Trzewikoswki de Lima G, Rodrigues TS, Portilho AI, Correa VA, Gaspar EB, De Gaspari E. Immune responses of meningococcal B outer membrane vesicles in middle-aged mice. Pathog Dis 2020;78:ftaa028. [PMID: 32639524 DOI: 10.1093/femspd/ftaa028] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
39 Sohn W, Tahrat H, Novy P, Bekkat-berkani R. Real-world implementation of 4-component meningococcal serogroup B vaccine (4CMenB): implications for clinical practices. Expert Review of Vaccines. [DOI: 10.1080/14760584.2022.2021881] [Reference Citation Analysis]
40 Patel C, Chiu CK, Beard FH, Crawford NW, Macartney K. One disease, two vaccines: challenges in prevention of meningococcal disease. Med J Aust 2020;212:453-456.e1. [PMID: 32279307 DOI: 10.5694/mja2.50567] [Reference Citation Analysis]
41 Marshall HS, Andraweera PH, Ward J, Kaldor J, Andrews R, Macartney K, Richmond P, Krause V, Koehler A, Whiley D, Giles L, Webby R, D’antoine H, Karnon J, Baird R, Lawrence A, Petousis-harris H, De Wals P, Greenwood-smith B, Binks M, Whop L. An Observational Study to Assess the Effectiveness of 4CMenB against Meningococcal Disease and Carriage and Gonorrhea in Adolescents in the Northern Territory, Australia—Study Protocol. Vaccines 2022;10:309. [DOI: 10.3390/vaccines10020309] [Reference Citation Analysis]
42 Huston J, Galicia K, Egelund EF. MenQuadfi (MenACWY-TT): A New Vaccine for Meningococcal Serogroups ACWY. Ann Pharmacother 2021;:10600280211039873. [PMID: 34459258 DOI: 10.1177/10600280211039873] [Reference Citation Analysis]
43 Birrell MT, Strachan J, Holmes NE, Stevens K, Howden BP, Franklin LJ, Ivan M, Kwong JC. Clinical manifestations of invasive meningococcal disease in Victoria with the emergence of serogroup W and serogroup Y Neisseria meningitidis. Intern Med J 2021;51:390-7. [PMID: 32043702 DOI: 10.1111/imj.14771] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
44 Wang B, Giles L, Andraweera P, Mcmillan M, Almond S, Beazley R, Mitchell J, Lally N, Ahoure M, Denehy E, Koehler A, Flood L, Marshall H. Effectiveness and impact of the 4CMenB vaccine against invasive serogroup B meningococcal disease and gonorrhoea in an infant, child, and adolescent programme: an observational cohort and case-control study. The Lancet Infectious Diseases 2022. [DOI: 10.1016/s1473-3099(21)00754-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
45 Van CP, Nguyen TT, Bui ST, Nguyen TV, Tran HTT, Pham DT, Trieu LP, Nguyen MD. Invasive Meningococcal Disease Remains a Health Threat in Vietnam People's Army. Infect Drug Resist 2021;14:5261-9. [PMID: 34916810 DOI: 10.2147/IDR.S339110] [Reference Citation Analysis]
46 Weil-Olivier C, Taha MK, Bouée S, Emery C, Loncle-Provot V, Nachbaur G, Beck E, Pribil C. Care pathways in invasive meningococcal disease: a retrospective analysis of the French national public health insurance database. Hum Vaccin Immunother 2022;:1-11. [PMID: 35192785 DOI: 10.1080/21645515.2021.2021764] [Reference Citation Analysis]
47 Esteves-jaramillo A, Koehler T, Jeanfreau R, Neveu D, Jordanov E, Singh Dhingra M. Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in ≥56-year-olds: A Phase III randomized study. Vaccine 2020;38:4405-11. [DOI: 10.1016/j.vaccine.2020.04.067] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
48 Knapper F. The changing face of meningococcal infection. Clin Infect Pract 2021;12:100083. [PMID: 34751256 DOI: 10.1016/j.clinpr.2021.100083] [Reference Citation Analysis]
49 Parikh SR, Campbell H, Bettinger JA, Harrison LH, Marshall HS, Martinon-Torres F, Safadi MA, Shao Z, Zhu B, von Gottberg A, Borrow R, Ramsay ME, Ladhani SN. The everchanging epidemiology of meningococcal disease worldwide and the potential for prevention through vaccination. J Infect 2020;81:483-98. [PMID: 32504737 DOI: 10.1016/j.jinf.2020.05.079] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 11.5] [Reference Citation Analysis]
50 Mcmillan M, Wang B, Koehler AP, Sullivan TR, Marshall HS. Impact of Meningococcal B Vaccine on Invasive Meningococcal Disease in Adolescents. Clinical Infectious Diseases 2021;73:e233-7. [DOI: 10.1093/cid/ciaa1636] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 5.0] [Reference Citation Analysis]
51 Willerton L, Lucidarme J, Walker A, Lekshmi A, Clark SA, Gray SJ, Borrow R. Increase in penicillin-resistant invasive meningococcal serogroup W ST-11 complex isolates in England. Vaccine 2021;39:2719-29. [PMID: 33858720 DOI: 10.1016/j.vaccine.2021.03.002] [Reference Citation Analysis]
52 Nolan T, Booy R, Marshall HS, Richmond P, Nissen M, Ziegler JB, Baine Y, Traskine M, Jastorff A, Van der Wielen M. Immunogenicity and Safety of a Quadrivalent Meningococcal ACWY-tetanus Toxoid Conjugate Vaccine 6 Years After MenC Priming as Toddlers. Pediatr Infect Dis J 2019;38:643-50. [PMID: 31116180 DOI: 10.1097/INF.0000000000002334] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
53 Hovmand N, Lundbo LF, Kronborg G, Voss SS, Sandholdt H, Hoffmann S, Valentiner-Branth P, Benfield T. Recent increased incidence of invasive serogroup W meningococcal disease: A retrospective observational study. Int J Infect Dis 2021;108:582-7. [PMID: 34102306 DOI: 10.1016/j.ijid.2021.05.086] [Reference Citation Analysis]
54 Säll O, Olofsson E, Jacobsson S. High genomic-based predicted strain coverage among invasive meningococcal isolates when combining Bexsero and Trumenba vaccines. Vaccine 2020;38:4374-8. [PMID: 32414653 DOI: 10.1016/j.vaccine.2020.04.074] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
55 Dubey AP, Hazarika RD, Abitbol V, Kolhapure S, Agrawal S. Mass gatherings: a review of the scope for meningococcal vaccination in the Indian context. Hum Vaccin Immunother 2021;17:2216-24. [PMID: 33605845 DOI: 10.1080/21645515.2020.1871572] [Reference Citation Analysis]
56 Flood L, McConnell M, Molchanoff L, Dodd Z, Sisnowski J, Fidock M, Miller T, Borresen K, Vogt H, Lane A. Lessons from a community vaccination programme to control a meningococcal disease serogroup W outbreak in remote South Australia, 2017. Western Pac Surveill Response J 2021;12:26-31. [PMID: 34094620 DOI: 10.5365/wpsar.2019.10.2.002] [Reference Citation Analysis]
57 Marshall GS, Ghaswalla PK, Bengtson LGS, Buikema AR, Bancroft T, Koep E, Novy P, Hogea CS. Low Meningococcal Vaccination Rates Among Patients With Newly Diagnosed Complement Component Deficiencies in the United States. Clin Infect Dis 2021:ciab917. [PMID: 34718466 DOI: 10.1093/cid/ciab917] [Reference Citation Analysis]
58 Kiral E, Yetimakman AF. Clinical and Laboratory Findings of 12 Children with Invasive Meningococcal Disease in Pediatric Intensive Care Unit. Crit Care Res Pract 2021;2021:9713918. [PMID: 34527377 DOI: 10.1155/2021/9713918] [Reference Citation Analysis]
59 Webber C, Peyrani P, Balmer P, Serra L. Persistence of bactericidal antibodies following primary and booster MenACWY-TT vaccination of toddlers: A review of clinical studies. Vaccine 2020;38:4236-45. [PMID: 32389497 DOI: 10.1016/j.vaccine.2020.02.048] [Reference Citation Analysis]